Veradigm ( (MDRX) ) has released a notification of late filing.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Veradigm Inc. has filed a Form 12b-25 notifying investors that it will delay its Annual Report on Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025. The company also remains behind on multiple Quarterly Reports on Form 10-Q (Quarter Report) and prior Annual Reports on Form 10-K (Yearly Report), leaving a large gap in its public financial record.
The primary reason for the ongoing delays is a history of internal control failures that led to misstatements in previously issued financial statements. Veradigm’s board has concluded that its 2020 and 2021 annual financials, as well as several 2021 and 2022 Quarterly Reports on Form 10-Q (Quarter Report), should no longer be relied upon, forcing extensive restatements and audits.
These issues pushed the company’s 2022 Form 10-K (Yearly Report), which included restated financials, all the way to March 18, 2025. Because of that knock-on delay and the need to prepare comprehensive Form 10-K (Yearly Report) filings for 2023 and 2024, Veradigm has still not filed any 2023 or 2024 Quarterly Reports on Form 10-Q (Quarter Report), the 2023 and 2024 Form 10-K (Yearly Report), or the 2025 Quarterly Reports on Form 10-Q (Quarter Report).
Veradigm does not provide a firm timetable for when the backlog of Historical Late Filings and the 2025 Form 10-K (Yearly Report) will be completed. Management states it is working diligently to get current, but explicitly warns investors that there can be no assurance about the definitive filing dates or the company’s ability to regain a Nasdaq listing.
The company indicates it does not currently expect significant changes in results of operations versus the prior year in the upcoming 2025 Form 10-K (Yearly Report). However, it cautions that audits for 2023, 2024, and 2025 could still uncover additional errors, material weaknesses, or adjustments, and all such expectations are framed as forward-looking statements subject to substantial risk.
Veradigm’s stock has already been delisted from Nasdaq after the exchange determined in early 2024 that the company was noncompliant with timely filing and annual meeting requirements. In response, Veradigm emphasizes its continuing remediation efforts around internal controls, financial reporting, and leadership, while warning that litigation and debt obligations may add further complexity.
The notification is signed on behalf of the company by Interim Chief Financial Officer Leland Westerfield on March 17, 2026. His signature underscores management’s formal acknowledgment of the delays and its obligation to move toward bringing Veradigm back into full reporting compliance, even as uncertainty remains for shareholders.
The most recent analyst rating on (MDRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Veradigm stock, see the MDRX Stock Forecast page.
More about Veradigm
Veradigm Inc. is a Chicago-based healthcare technology company previously listed on the Nasdaq Global Select Market. The firm provides software and data solutions to medical providers, payers, and life sciences companies. Its business depends heavily on trust in its financial reporting and access to public capital markets, making prolonged reporting delays particularly sensitive for investors.
Average Trading Volume: 238,518
Technical Sentiment Signal: Strong Sell
Current Market Cap: $495.5M
See more data about MDRX stock on TipRanks’ Stock Analysis page.